Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
Connect with a provider A licensed medical provider will determine if treatment is right for you
Image Credit: Love Employee / Shutterstock In a recent study published in the journal BMJ Medicine , researchers conducted a target trial emulation to assess associations between different scenarios of glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment and the risk of major adverse cardiovascular events (MACE)
Pharmaceutical interventions achieve dramatic outcomes documented in clinical trials
Importantly, localized increases in GLP-1, such as that occur in the gut and portal vein, often have a more profound effect than systemic elevations, emphasizing the therapeutic potential of targeting regional activity rather than relying solely on systemic concentrations
Miura, M
Cysteine-rich protein 61 (CCN1) domain-specific stimulation of matrix metalloproteinase-1 expression through V3 integrin in human skin fibroblasts
